Клинические рекомендации ОССН-РКО-РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика …
ВЮ Мареев, ИВ Фомин, ФТ Агеев, ЮЛ Беграмбекова… - Кардиология, 2018 - lib.ossn.ru
1–«МНОЦ МГУ им. МВ Ломоносова», 119192, Москва, Ломоносовский пр-кт, д. 27, корп.
10 2–ФГБОУ ВО «ПИМУ» МЗ РФ, 603950, Нижний Новгород, пл. Минина и Пожарского …
10 2–ФГБОУ ВО «ПИМУ» МЗ РФ, 603950, Нижний Новгород, пл. Минина и Пожарского …
Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany
K Keller, L Hobohm, M Ebner, KP Kresoja… - European heart …, 2020 - academic.oup.com
Aims Pulmonary embolism (PE) is the third most common cardiovascular cause of death;
systemic thrombolysis is potentially lifesaving treatment in patients presenting with …
systemic thrombolysis is potentially lifesaving treatment in patients presenting with …
Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: first update 2016
SA Kozek-Langenecker, AB Ahmed… - European Journal of …, 2017 - journals.lww.com
The management of perioperative bleeding involves multiple assessments and strategies to
ensure appropriate patient care. Initially, it is important to identify those patients with an …
ensure appropriate patient care. Initially, it is important to identify those patients with an …
Rivaroxaban or aspirin for extended treatment of venous thromboembolism
JI Weitz, AWA Lensing, MH Prins… - … England Journal of …, 2017 - Mass Medical Soc
Background Although many patients with venous thromboembolism require extended
treatment, it is uncertain whether it is better to use full-or lower-intensity anticoagulation …
treatment, it is uncertain whether it is better to use full-or lower-intensity anticoagulation …
Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report
Background We update recommendations on 12 topics that were in the 9th edition of these
guidelines, and address 3 new topics. Methods We generate strong (Grade 1) and weak …
guidelines, and address 3 new topics. Methods We generate strong (Grade 1) and weak …
[HTML][HTML] Russian heart failure society, Russian society of cardiology. Russian scientific medical society of internal medicine guidelines for heart failure: chronic (CHF) …
VY Mareev, IV Fomin, FT Ageev, YL Begrambekova… - Kardiologiia, 2018 - lib.ossn.ru
РЕКОМЕНДАЦИИ, СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ, ХРОНИЧЕСКАЯ СЕРДЕЧНАЯ
НЕДОСТАТОЧНОСТЬ, ОСТРАЯ ДЕКОМПЕНСАЦИЯ СЕРДЕЧНОЙ …
НЕДОСТАТОЧНОСТЬ, ОСТРАЯ ДЕКОМПЕНСАЦИЯ СЕРДЕЧНОЙ …
Deep vein thrombosis and pulmonary embolism
M Di Nisio, N van Es, HR Büller - The Lancet, 2016 - thelancet.com
Deep vein thrombosis and pulmonary embolism, collectively referred to as venous
thromboembolism, constitute a major global burden of disease. The diagnostic work-up of …
thromboembolism, constitute a major global burden of disease. The diagnostic work-up of …
[HTML][HTML] Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical …
S Kaatz, D Ahmad, AC Spyropoulos… - Journal of Thrombosis …, 2015 - Elsevier
Methods We limited our literature review to trials in patients with AF and VTE because the
work of the Bleeding Academic Research Consortium has already addressed this issue in …
work of the Bleeding Academic Research Consortium has already addressed this issue in …
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
Background Coronary artery disease is a major cause of morbidity and mortality worldwide,
and is a consequence of acute thrombotic events involving activation of platelets and …
and is a consequence of acute thrombotic events involving activation of platelets and …
Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical …
JA Frontera, JJ Lewin III, AA Rabinstein, IP Aisiku… - Neurocritical care, 2016 - Springer
Background The use of antithrombotic agents, including anticoagulants, antiplatelet agents,
and thrombolytics has increased over the last decade and is expected to continue to rise …
and thrombolytics has increased over the last decade and is expected to continue to rise …